Multiple Sclerosis In The Crossfire 2010: The State of Disease-Modifying Therapies
The State of Disease-Modifying Therapies
The recent FDA-approval of the first oral disease-modifying therapy for multiple sclerosis has the potential to be a game-changer — but will it? Parenteral disease-modifying therapies have been available since the early 1990's, and have a heritage of efficacy and well-characterized safety profiles.
In this year's program, Dr. Omar Khan and his panel of MS specialists will discuss the state of disease-modifying therapies as we enter the age of oral therapy. Part 1 includes evaluating the response to therapy, and the benefit/risk profile of the first oral immunosuppressant agent, fingolimod (Gilenya™). In Part 2, the specialists consider the next generation of MS therapeutics, both oral and injectable, and debate the use of imaging in clinical practice.
MS In The Crossfire 2010
Recorded live on October 5, 2010, at the Studios of Detroit Public Television
Each part of the 2010 program is eligible for 1 AMA PRA Category 1 Credit™, for a total of 2.0 credits.
Sponsored and Supported by:
This continuing medical education activity is jointly sponsored by Peer Health Communications and Ciné-Med, Inc.
This activity is supported by an educational grant from Teva Neuroscience.
2010 Distinguished Faculty
Omar Khan, MD, FRCP
Moderator
Edward J. Fox, MD, PhD
Panelist
Bruce Cree, MD, PhD, MCR
Panelist
Fred D. Lublin, MD
Panelist
In the Crossfire 2009: New Therapies for MS
Data and insights about the plethora of new therapies on the horizon.
In the Crossfire 2008: The Emerging Face of MS
Immunopathology, imaging study data and the clinical effects of disease-modifying therapy.